299 related articles for article (PubMed ID: 29356308)
1. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma After Curative Resection.
Chen JL; Lao XM; Lin XJ; Xu L; Cui BK; Wang J; Lin GH; Shuang ZY; Mao YZ; Huang X; Yun JP; Jin JT; Li SP
Medicine (Baltimore); 2016 Feb; 95(5):e2665. PubMed ID: 26844496
[TBL] [Abstract][Full Text] [Related]
3. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.
Yoon JS; Song BG; Lee JH; Lee HY; Kim SW; Chang Y; Lee YB; Cho EJ; Yu SJ; Sinn DH; Kim YJ; Lee JH; Yoon JH
BMC Cancer; 2019 May; 19(1):523. PubMed ID: 31151419
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Chen CL; Pan QZ; Zhao JJ; Wang Y; Li YQ; Wang QJ; Pan K; Weng DS; Jiang SS; Tang Y; Zhang XF; Zhang HX; Zhou ZQ; Zeng YX; Xia JC
Oncoimmunology; 2016 Jul; 5(7):e1176653. PubMed ID: 27622026
[TBL] [Abstract][Full Text] [Related]
8. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
[TBL] [Abstract][Full Text] [Related]
9. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
Zhou ZQ; Zhao JJ; Pan QZ; Chen CL; Liu Y; Tang Y; Zhu Q; Weng DS; Xia JC
J Immunother Cancer; 2019 Aug; 7(1):228. PubMed ID: 31455411
[TBL] [Abstract][Full Text] [Related]
11. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients.
Huang ZM; Li W; Li S; Gao F; Zhou QM; Wu FM; He N; Pan CC; Xia JC; Wu PH; Zhao M
J Immunother; 2013 Jun; 36(5):287-93. PubMed ID: 23719239
[TBL] [Abstract][Full Text] [Related]
12. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.
Hui D; Qiang L; Jian W; Ti Z; Da-Lu K
Dig Liver Dis; 2009 Jan; 41(1):36-41. PubMed ID: 18818130
[TBL] [Abstract][Full Text] [Related]
14. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Cancer Immunol Immunother; 2019 Jan; 68(1):23-32. PubMed ID: 30232520
[TBL] [Abstract][Full Text] [Related]
15. A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Pan QZ; Wang QJ; Dan JQ; Pan K; Li YQ; Zhang YJ; Zhao JJ; Weng DS; Tang Y; Huang LX; He J; Chen SP; Ke ML; Chen MS; Wicha MS; Chang AE; Zeng YX; Li Q; Xia JC
Sci Rep; 2015 Mar; 5():9202. PubMed ID: 25776856
[TBL] [Abstract][Full Text] [Related]
16. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
[TBL] [Abstract][Full Text] [Related]
17. Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review.
Cai XR; Li X; Lin JX; Wang TT; Dong M; Chen ZH; Jia CC; Hong YF; Lin Q; Wu XY
Oncotarget; 2017 May; 8(19):31318-31328. PubMed ID: 28412743
[TBL] [Abstract][Full Text] [Related]
18. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
19. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis.
He G; Zheng C; Huo H; Zhang H; Zhu Z; Li J; Zhang H
Int Immunopharmacol; 2016 Nov; 40():436-442. PubMed ID: 27716591
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-cytokine killer combined with microwave ablation reduced recurrence for hepatocellular carcinoma compared to ablation alone.
Wang L; Li X; Dong XJ; Yu XL; Zhang J; Cheng ZG; Han ZY; Liu FY; Yu J; Liang P
Technol Health Care; 2024; 32(3):1819-1834. PubMed ID: 38393935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
